
RxSight (RXST) Stock Forecast & Price Target
RxSight (RXST) Analyst Ratings
Bulls say
RxSight Inc. demonstrates a robust financial trajectory, highlighted by a year-over-year increase in operating expenses of only $2.0 million, indicating a controlled growth in costs amidst rising business activity. The company is poised for sustained double-digit revenue growth, supported by a strategic focus on increasing utilization rates among its growing light adjustable lens (LDD) installed base and enhancing volumes through targeted engagement initiatives. Furthermore, management has raised gross margin guidance to 76-77% for 2025, reflecting optimism about operational efficiency and profitability, alongside a careful management of operating expenses anticipated in the range of $145-155 million.
Bears say
RxSight Inc. has experienced a notable decline in monthly utilization of its light adjustable lenses (LALs), falling to 8.0 LALs per laser delivery device (LDD) in 3Q25 from 8.7 in 2Q25 and 10.1 in 3Q24, indicating a negative trend in operational efficiency. The company's revenue also dropped by 14% year-over-year to $30.3 million, coinciding with a significant decrease in LDD placements, which plummeted by 68% year-over-year and 38% quarter-over-quarter to only 25 units in 2Q25, trailing behind consensus expectations. Additionally, key risks remain, including limited adoption of their technology due to the necessity for an incremental capital investment, challenges in commercial execution, growing competition in the intraocular lens market, and concerns over the potential need for dilutive financing.
This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.
RxSight (RXST) Analyst Forecast & Price Prediction
Start investing in RxSight (RXST)
Order type
Buy in
Order amount
Est. shares
0 shares